The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.
A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.
